Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a ketone drink shield kidneys?

NCT ID NCT06867471

Disease control Sponsor: Gødstrup Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing whether a ketone supplement drink can reduce protein in the urine and improve kidney function in people with chronic kidney disease or polycystic kidney disease. The study includes 45 participants who receive either the ketone drink or a placebo for four weeks, then switch to the other treatment after a two-week break. The main measures are changes in urine protein and kidney filtration rate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a ketone dietary supplement drink called Ketone-IQ
What this could lead to
If it works, this could point toward a simple dietary supplement that helps protect kidney function in people with chronic kidney disease or polycystic kidney disease.
What could go wrong
This is a small, early-stage study with 45 participants. The supplement may not change protein levels or kidney function, and it could cause digestive upset or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Sep 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Study A (patients with CKD): * ACR \> 200 mg/g \<3000 mg/g * eGFR \>30 ml/min/1,73m2 * Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion * Safe contraception if women in childbearing age Study B (patients with PKD): * Prior diagnose with PKD * eGFR \>30 ml/min/1,73m2 * Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion * Safe contraception if women in childbearing age Exclusion Criteria (Study A+B) * Diabetes Mellitus type 1 * Heart Failure * Liver Disease * Kidney transplant * Malignant diseases (except skin cancer) * Recent acute myocardial infarction (AMI), apoplexia/transient ischemic attack (TIA) (within 3 months of inclusion) * Pregnancy or breast feeding * Alcohol or drug abuse * Periodic fasting within four weeks of inclusion * Routinely intake of ketogenic diet within four weeks of inclusion * Treatment with nitrate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ketosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Ketosis polycystic kidney disease proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ketosis Polycystic kidney diseases Proteinuria Renal insufficiency, chronic

Contacts and locations

Locations

  • University Clinic in Nephrology and Hypertension, Gødstrup Region Hospital

    Herning, Jutland, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.